MedTrace Logo

Effects of Gastric Bypass on Blood Levels of Duloxetine

NCT00989157 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-08-11

Study results available
· View outcomes & findings →

Summary

This study aims to determine the difference, if any, in the pharmacokinetics of duloxetine between patients who are nine to fifteen months post Roux-en-Y Bariatric Surgery and control subjects matched for body mass index (BMI), age and gender.

Conditions

  • Bariatric Surgery

Interventions

DRUG

Duloxetine

Single dose of 60 mg of duloxetine

Sponsors & Collaborators

  • University of North Dakota

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Neuropsychiatric Research Institute, Fargo, North Dakota

    lead OTHER

Principal Investigators

  • James L Roerig, PharmD, BCPP · Neuropsychiatric Research Institute and University of North Dakota

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-10-31
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00989157 on ClinicalTrials.gov